The anti‐CD19 CAR‐T medications are the first products that received regulatory approval for treatment of patients with B‐cell ALL (B‐ALL) and B‐cell non‐Hodgkin lymphomas (NHL). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.